CHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients at high risk of recurrence of cutaneous squamous-cell carcinoma (SCC), a phase III randomized trial showed.

Among 415 patients who underwent surgical resection and postoperative radiotherapy, a significant improvement in DFS was seen in those who received cemiplimab versus those who received placebo (24 vs 65 events; HR 0.32, 95% CI 0.20-0.51, P <0.001), reported Danny Rischin, MD, of the Peter MacCallum Cancer Centre in Melbourne, Australia.

The estimated 24-month DFS rate was 87.1% with the PD-1 inhibitor and 64.1% with placebo, Rischin said at the American Society of Clinical Oncology (ASCO) annual meeting.

"Cemiplimab is the only systemic therapy to demon

See Full Page